Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment

2008 ◽  
Vol 41 (10-11) ◽  
pp. 836-840 ◽  
Author(s):  
Ayşe Yeşim Göçmen ◽  
Emel Şahin ◽  
Hüseyin Koçak ◽  
Murat Tuncer ◽  
Saadet Gümüşlü
Keyword(s):  
Nitric Oxide ◽  
Lipid Peroxidation ◽  
Peritoneal Dialysis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Asymmetric Dimethylarginine ◽  
Dialysis Treatment ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Discover, analysis, and interpretation of problems and comparing satisfaction of hemodialysis and peritoneal dialysis patients: patients' perspective

2020 ◽  
Author(s):  
Ghazanfar Rafiee ◽  
Jamshid Roozbeh
Keyword(s):  
Peritoneal Dialysis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Dialysis Patients ◽  
Dialysis Treatment ◽  
Patient’S Satisfaction ◽  
Exploratory Approach ◽  
Dialysis Method ◽  
Stage Renal Disease ◽  
End Stage

Abstract Background: End-stage renal disease is an irreversible and progressive loss of kidney function and it can be fatal without hemodialysis, peritoneal dialysis or kidney transplantation. Hemodialysis is a type of treatment where the patient is connected to a machine through a catheter via veins for twice or three times a week for approximately four hours. Alternatively, peritoneal dialysis is carried out with a plastic catheter insertion into the abdomen through which dialysis fluid (glucose) enters and is taken out. This study aimed to discover, analyze, interpret and compare end-stage renal disease patient's satisfaction with hemodialysis and peritoneal dialysis with an emphasis on complications and problems that was created during dialysis treatment.Methods: this study a qualitative exploratory approach was used at Shiraz hemodialysis and peritoneal dialysis centers 2017-2018. In these centers there were 345 ESRD patients who were receiving dialysis. A purposeful sample of 35 hemodialysis and 30 peritoneal dialysis patients were interviewed. The data were collected through interview. Each session lasted for 50 minutes. Initially 12 open-ended questions were developed and used to stimulate discussions in sessions. Directed content analysis was used for analyzing the transcribed data. After giving a code to each line or incidence, codes were then compared for similarity and differences, merged together, and categorized. Results: Themes of Fatigue experience, Insomnia, Wasting time, Travel and leisure time activities limitations, Hypotension, Dissatisfaction and satisfaction with hemodialysis, Peritoneal catheter problems, peritoneal dialysis difficulties and limitations, satisfaction from peritoneal dialysis emerged. Each dialysis method has its own problems. Some problems and limitations were more emphasized on by patients. Conclusion: Each dialysis method has its own problems. Some problems and limitations were more emphasized on by patients.

scholarly journals Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis

1999 ◽  
Vol 276 (5) ◽  
pp. F794-F797 ◽  
Author(s):  
Rebecca J. Schmidt ◽  
Stanley Yokota ◽  
Timothy S. Tracy ◽  
Michael I. Sorkin ◽  
Chris Baylis
Keyword(s):  
Nitric Oxide ◽  
Peritoneal Dialysis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Oxidation Products ◽  
No Oxidation ◽  
No Production ◽  
Synthase Inhibitor ◽  
Stage Renal Disease ◽  
End Stage

To test the hypothesis that nitric oxide (NO) deficiency occurs in end-stage renal disease (ESRD), NO oxidation products (NO2 + NO3 = NOx) and cGMP were measured in blood, urine, and dialysate effluent of peritoneal dialysis (PD) patients and compared with blood and urine of healthy subjects. All subjects were on a controlled low-nitrate diet (∼330 μmol/day). NOx and cGMP outputs were significantly reduced in PD patients (334 ± 50 μmol/24 h and 55 ± 13 nmol/24 h, respectively) vs. controls (823 ± 101 μmol/24 h and 149 ± 46 nmol/24 h). Plasma arginine was borderline low, plasma citrulline was elevated and plasma levels of the endogenous NO synthase inhibitor asymmetric dimethylarginine were approximately five time higher in PD patients (2.2 ± 0.3 μM) vs. controls (0.4 ± 0.1 μM). Although blood pressure (BP) was not different between groups at the time of study, 10 of 11 PD patients were on medication for hypertension. These studies demonstrate that total NO production is low in ESRD, and with appropriate caution, we conclude that this NO deficiency may contribute to the increased BP that occurs in ESRD.

Relationship between Salt Intake, Nitric Oxide and Asymmetric Dimethylarginine and Its Relevance to Patients with End-Stage Renal Disease

2002 ◽  
Vol 20 (5) ◽  
pp. 466-468 ◽  
Author(s):  
Tomohiro Osanai ◽  
Naoto Fujiwara ◽  
Masayuki Saitoh ◽  
Satoko Sasaki ◽  
Hirofumi Tomita ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Asymmetric Dimethylarginine ◽  
Salt Intake ◽  
Stage Renal Disease ◽  
End Stage

Outcomes of infants <28 days old treated with peritoneal dialysis for end-stage renal disease

2009 ◽  
Vol 24 (10) ◽  
pp. 2035-2039 ◽  
Author(s):  
Michelle N. Rheault ◽  
Jurat Rajpal ◽  
Blanche Chavers ◽  
Thomas E. Nevins
Keyword(s):  
Peritoneal Dialysis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

High Accumulation of Endothelial Nitric Oxide Synthase (ecNOS):A Gene Polymorphism in Patients with End-Stage Renal Disease

Nephron ◽  
1998 ◽  
Vol 79 (3) ◽  
pp. 360-361 ◽  
Author(s):  
Keitaro Yokoyama ◽  
Toshihiko Tsukada ◽  
Hiroaki Matsuoka ◽  
Sigeko Hara ◽  
Akira Yamada ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Gene Polymorphism ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Endothelial Nitric Oxide Synthase ◽  
High Accumulation ◽  
Stage Renal Disease ◽  
End Stage ◽  
Oxide Synthase ◽  
Endothelial Nitric Oxide
Sign in / Sign up

Export Citation Format

Share Document